<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2403">
  <stage>Registered</stage>
  <submitdate>28/05/2009</submitdate>
  <approvaldate>28/05/2009</approvaldate>
  <nctid>NCT00925587</nctid>
  <trial_identification>
    <studytitle>Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease</studytitle>
    <scientifictitle>A Multicenter, Randomised, Double-Blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2006-003173-27</secondaryid>
    <secondaryid>20060163</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anemia</healthcondition>
    <healthcondition>Chronic Kidney Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - darbepoetin alfa

Active Comparator: Q2W - Q2W administration of darbepoetin alfa.

Active Comparator: QM - QM administration of darbepoetin alfa


Treatment: drugs: darbepoetin alfa
Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33) - The Adjusted Analysis is the primary analysis and includes treatment group and baseline Hb value as covariates. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the mean difference is above -0.5g/dL.</outcome>
      <timepoint>Baseline Week 33</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of Both a Hb &gt;= 10.0 g/dL and a &gt;= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.</outcome>
      <timepoint>Baseline to Week 33</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Baseline</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 3</outcome>
      <timepoint>Week 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 5</outcome>
      <timepoint>Week 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 7</outcome>
      <timepoint>Week 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 9</outcome>
      <timepoint>Week 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 11</outcome>
      <timepoint>Week 11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 13</outcome>
      <timepoint>Week 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 15</outcome>
      <timepoint>Week 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 17</outcome>
      <timepoint>Week 17</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 19</outcome>
      <timepoint>Week 19</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 21</outcome>
      <timepoint>Week 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 23</outcome>
      <timepoint>Week 23</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 25</outcome>
      <timepoint>Week 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 27</outcome>
      <timepoint>Week 27</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 29</outcome>
      <timepoint>Week 29</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 31</outcome>
      <timepoint>Week 31</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hb at Week 33</outcome>
      <timepoint>Week 33</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 1 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 3 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 5 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 7 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 9 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 11 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 13 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 15 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 17 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 17</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 19 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 19</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 21 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 23 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 23</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 25 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 27 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 27</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 29 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 29</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose at Week 31 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 31</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33) - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Weeks 29-33</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 3 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 5 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 5</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 7 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 9 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 9</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 11 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 13 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 15 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 17 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 17</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 19 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 19</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 21 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 23 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 23</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 25 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 25</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 27 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 27</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 29 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 29</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at Week 31 - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Week 31</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dose of Darbepoetin Alfa at the First Achievement of a Hb =10.0 g/dL and a =1.0 g/dL Increase From Baseline (Weeks 1-33) - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Weeks 1-33</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Achievement of a Hb =10.0 g/dL and a =1.0 g/dL Increase From Baseline (Weeks 1-33)</outcome>
      <timepoint>Weeks 1-33</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33) - Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period</outcome>
      <timepoint>Evaluation Period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  = 18 years of age

          -  Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)

          -  Two consecutive screening Hb values taken at least 7 days apart must each be &lt;10.0
             g/dL

          -  TSAT = 15%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Upper or lower GI bleeding within 6 months before enrolment

          -  ESA use within 12 weeks before enrolment

          -  Uncontrolled hypertension

          -  Systemic haematologic disorders

          -  Prior history within 12 weeks before enrollment of events including: Acute myocardial
             ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart
             failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis,
             thromboembolism.

          -  Grand mal seizure within 6 months prior to enrolment

          -  Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5
             years prior to enrolment.

          -  Red blood cell transfusion within 12 weeks prior to enrolment

          -  Androgen therapy within 8 weeks prior to enrolment

          -  Pregnancy or breast feeding, or inadequate contraception

          -  Currently receiving immunosuppressive therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>358</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Research Site - Gosford</hospital>
    <hospital>Research Site - Liverpool</hospital>
    <hospital>Research Site - New Lambton</hospital>
    <hospital>Research Site - Randwick</hospital>
    <hospital>Research Site - Cairns</hospital>
    <hospital>Research Site - Box Hill</hospital>
    <hospital>Research Site - Footscray</hospital>
    <hospital>Research Site - Parkville</hospital>
    <hospital>Research Site - Reservoir</hospital>
    <postcode>2250 - Gosford</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2305 - New Lambton</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3073 - Reservoir</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>LiÃ¨ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Chrudim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Jilemnice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Liberec 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Novy Jicin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 4 - Nusle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 6</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Slavkov u Brna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Sternberk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Usti nad Orlici</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Roskilde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Viborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Ã…rhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Annonay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Metz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montivilliers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poissy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Priest en Jarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bernkastel-Kues</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coesfeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>DÃ¼sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leverkusen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Alexandroupoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Larissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Baja</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Esztergom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekszard</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szombathely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Zalaegerszeg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Hadera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Albano Laziale RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cagliari</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lecco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Daugavpils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Valmiera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Ventspils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Coahuila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Morelos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>QuerÃ©taro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis PotosÃ-</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Choszczno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Golub-Dobrzyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Koscierzyna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Koszalin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Legnica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zamosc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Evora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Faro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>SetÃºbal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Krgujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Zemun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Galanta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Namestovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Sala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trstena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Zvolen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Jesenice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Novo mesto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Sempeter pri Gorici</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Slovenj Gradec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>AndalucÃ-a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>CataluÃ±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>PaÃ-s Vasco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hull</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle Upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Shrewsbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Stevenage</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Stoke On Trent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Swansea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wolverhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether once monthly (QM) dosing of darbepoetin
      alfa is non-inferior to that of once every 2 week (Q2W) dosing of darbepoetin alfa for the
      correction of anemia in patients with Chronic Kidney Disease who are not receiving dialysis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00925587</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>